SEC EDGAR CompanyFacts fact · reporting period
Revance Therapeutics, Inc.: revenue
One fact, its scope and the complete path back to the official record.
Reported value
$413.000k{"amount": 413000, "concept": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "currency": "USD"}- Metric
- revenue
- Period
- 2019-01-01 – 2019-12-31
- Status
- current
- Source
- SEC EDGAR CompanyFacts
Provenance
Source licenseUS-PD-17USC105
Retrieved2026-08-19T14:41:26.423200+02:00
Raw response SHA-256
f7bde1a401b286c74a2fd824ee1df541…Official-identifier path
https://factanker.com/fact/sec/cik-0001479290/revenue/2019-12-31 (CIK, metric, reporting date)History
- supersedes {"amount": 413000, "concept": "us-gaap:Revenues", "currency": "USD"} (evidence 0001479290-20-000042)
Why this page exists
The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.